Cytiva, a global life sciences leader, entered four agreements during its debut at the third China International Import Expo on Tuesday. [Photo provided to chinadaily.com.cn]

Cytiva, a global life sciences leader, entered four agreements during its debut at the third China International Import Expo on Tuesday, underscoring the company's commitment to bolster China's biotechnology industry and foster a healthy local ecosystem.

In China's most high-profile import-themed fair, Cytiva signed a string of deals with Wego, Zhifei, Clover and Jinbo, pledging to invest in the fields of manufacturing, bioprocess development and research to accelerate the development and manufacture of therapeutics and benefit patients in the country and beyond.

"The collaboration with our local partners displays our long-term commitment to the Chinese market, and shows how our 'in China for China' strategy could also benefit the broader Asia Pacific region," said Yu Lihua, general manager of Cytiva China.

Cytiva and Wego announced plans to triple single-use manufacturing capacity in Asia Pacific to produce bags, components and other customized products. The expanded capacity also responds to surging needs from neighboring markets like Japan and South Korea.

Another highlight was Cytiva's support of Clover Biopharmaceuticals to scale up the output of its vaccine candidate, paving the way for the production of COVID-19 vaccines in the future.

"Our aim is always to provide more accessible technology and products to our customers and patients, and no one can do it alone," Yu said.